Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Evocutis
Evocutis
Activities:
Regulatory
Research & Development
Skin Care
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Skin Care
Venn Life Sciences acquires trading assets of Evocutis
Including intellectual property rights to Labskin and anti-acne compound SYN1113
Regulatory
Evocutis and Bradford University Collaborate on pigmented LabSkin
Aim to discover improved ways of investigating common pigment-related skin conditions
Regulatory
Evocutis secures first contracts for LabSkin living skin equivalent
Offers an alternative to ethically sensitive and expensive animal and human volunteer testing
Research & Development
Evocutis joins European platform to promote alternatives to animal testing
After making presentation about its LabSkin technology
Ingredients
Syntopix develops microemulsions for healthcare and cosmetic products
Identifies two green surfactants for oral care
Manufacturing
Syntopix plans to buy Leeds Skin
Key attraction of acquisition is Leeds Skin’s LabSkin technology
Ingredients
Syntopix to develop new microemulsions
Wins support from Intelligent Formulation
Subscribe now